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OBJECTIVE—To study whether modiﬁcation of LDL by meth-
ylglyoxal (MG), a potent arginine-directed glycating agent that is
increased in diabetes, is associated with increased atherogenicity.
RESEARCH DESIGN AND METHODS—Human LDL was
isolated and modiﬁed by MG in vitro to minimal extent (MGmin-
LDL) as occurs in vivo. Atherogenic characteristics of MGmin-LDL
were characterized: particle size, proteoglycan-binding, suscepti-
bility to aggregation, LDL and non-LDL receptor–binding, and
aortal deposition. The major site of modiﬁcation of apolipopro-
tein B100 (apoB100) modiﬁcation was investigated by mass spec-
trometric peptide mapping.
RESULTS—MGmin-LDL contained 1.6 molar equivalents of MG
modiﬁcation—mostly hydroimidazolone—as found in vivo. MGmin-
LDL had decreased particle size, increased binding to proteogly-
cans, and increased aggregation in vitro. Cell culture studies
showed that MGmin-LDL was bound by the LDL receptor but not
by the scavenger receptor and had increased binding afﬁnity for
cell surface heparan sulfate–containing proteoglycan. Radiotracer
studies in rats showed that MGmin-LDL had a similar fractional
clearance rate in plasma to unmodiﬁed LDL but increased parti-
tioning onto the aortal wall. Mass spectrometry peptide mapping
identiﬁed arginine-18 as the hotspot site of apoB100 modiﬁcation
in MGmin-LDL. A computed structural model predicted that MG
modiﬁcation of apoB100 induces distortion, increasing exposure
of the N-terminal proteoglycan–binding domain on the surface of
LDL. This likely mediates particle remodeling and increases pro-
teoglycan binding.
CONCLUSIONS—MG modiﬁcation of LDL forms small, dense
LDL with increased atherogenicity that provides a new route to
atherogenic LDL and may explain the escalation of cardiovascu-
lar risk in diabetes and the cardioprotective effect of metformin.
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C
ardiovascular disease (CVD) is the major cause
of premature death in individuals with diabetes
and is mainly driven by increased arterial ath-
erosclerosis. Increased risk of atherosclerosis is
associated with high levels of LDL and, more particularly,
with high levels of small dense LDL (sdLDL) (1). The risk
of CVD is increased two- to threefold in diabetes, where
the typical increase of sdLDL is two- to threefold (2).
Plasma levels of sdLDL correlate with carotid intima-media
thickness (3) and are linked to the risk of CVD (4).
The processes associated with the transformation of
LDL to sdLDL are not fully understood. Cholesterol ester
transfer protein–mediated cholesterol ester/triglyceride
exchange between VLDL to LDL with hepatic lipase-
mediated hydrolysis is involved, but other metabolic fac-
tors, genetic factors, and therapeutic agents inﬂuence the
processes involved (5,6). Initially, sdLDL was proposed as
having increased susceptibility to oxidation ex vivo (7),
but surprisingly, some studies of patients with diabetes
have not found this (8). Nevertheless, sdLDL has charac-
teristics of increased atherogenicity—increased afﬁnity
for arterial proteoglycan (PG) and cell surface non-LDL
receptor–binding sites (9,10). Increased atherogenicity of
sdLDL may be partly linked to nonoxidative modiﬁcations
of its major lipoprotein, apolipoprotein (apo) B100.
Metabolic factors linked to increased sdLDL may be
evident in diabetes. Methylglyoxal (MG) is a potent
dicarbonyl glycating agent formed by the degradation of
triosephosphate and metabolized by the glutathione-
dependent glyoxalase system( 1 1 ) .T h ep l a s m ac o n c e n -
tration of MG is increased two- to ﬁvefold in patients
with diabetes (12), which is likely linked to increased
ﬂux of formation of MG in hyperglycemia, associated with
diabetes (13) and downregulation of expression of glyoxalase
1b yi n ﬂammatory signaling (14). Glycation of LDL by
MG is directed to arginine residues in apoB100, form-
ing mainly the hydroimidazolone Nd-(5-hydro-5-methyl-
4-imidazolon-2-yl)-ornithine residues (MG-H1), a major
advanced glycation end product (AGE) in physiologic
systems (15) (Fig. 1A). MG-H1 is a major AGE of LDL in
healthy people and is increased up to ﬁvefold in the LDL of
individuals with type 2 diabetes (16). Diabetic patients re-
ceiving treatment with metformin had decreased plasma
concentrations of MG (17) and decreased MG-H1–modiﬁed
LDL (16).
In this report, we describe the effect on atherogenicity
of modiﬁcation of human LDL by MG to physiologic
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ORIGINAL ARTICLEextent. The ﬁndings reveal that MG modiﬁcation is a pre-
viously unrecognized route to increased atherogenic sdLDL
in diabetes.
RESEARCH DESIGN AND METHODS
LDL and other materials. LDL was isolated from human peripheral venous
plasma (16). LDL minimally modiﬁed by MG (MGmin-LDL) and LDL minimally
modiﬁed by glucose (AGEmin-LDL) were prepared and characterized as de-
scribed (16). Mildly oxidized LDL was prepared by incubation of LDL (1 mg/mL)
with copper sulfate (10 mmol/L) in sodium PBS for 24 h at 37°C, and the content
of thiobarbituric acid reactive substances (TBARS) was 3.13 6 0.88 nmol/mg
protein compared with 0.81 6 0.45 nmol/mg protein in control LDL (16).
Where required, LDL preparations were radiolabeled with
125I using pre-
coated iodination tubes (Fisher Scientiﬁc UK Ltd, Loughborough, U.K.),
according to the manufacturer’s protocol, and puriﬁed by gel ﬁltration chro-
matography. [
125I]LDL had speciﬁc activity of 337 counts per minute (cpm)/ng
protein.
Mouse monoclonal anti-MG-H1 antibody clone 1H7G5 was a gift from
Professor Michel Brownlee (Albert Einstein College of Medicine, Bronx, NY).
The PGs and glycosaminoglycan used were biglycan and aggrecan from bovine
articular cartilage, perlecan from Engelbreth-Holm-Swarm tumor–secreted
extracellular matrix (18), and heparin from porcine intestinal mucosa (Sigma-
Aldrich, Poole, U.K.; cat nos. B8041, A1960, H4777, and H3149, respectively).
Protein concentration of LDL and related derivatives was determined by
Bradford and EZQ methods (Invitrogen, Paisley, U.K.).
Electron microscopy. LDL particle size was assessed by electron microscopy.
LDL preparations (;150 mg/mL) were applied to grids coated with carbon ﬁlm
containing polystyrene-latex beads of 0.112 mm diameter calibration standard
and stained with 2% uranyl acetate (n =3 –5 grids for each sample). Samples
were examined on a JEOL 2011 transmission electron microscope (200 kV
LaB6 cathode; Tokyo, Japan) with a Gatan Ultrascan camera (Pleasanton,
CA). The diameter was measured in Gatan Digital Micrograph software using
a proﬁle plot.
Cell-free binding of LDL to biglycan, aggrecan, and perlecan and vortex-
stimulated aggregation. Binding of LDL to PGs was studied in a cell-free
systembyincubationofLDLwithPG-coatedandblockedmicroplatewells(19).
Polystyrene Maxisorp 96-well plates (Nunc, Rochester, NY) were coated with
biglycan, aggrecan, or perlecan (50 mg/mL; 100 mL) in PBS overnight at 4°C
and blocked with 3% BSA, 1% fat-free milk powder, and 0.05% Tween 20 in PBS
for 1 h at 37°C. LDL derivatives in 1% BSA, 140 mmol/L NaCl, 2 mmol/L CaCl2,
2 mmol/L MgCl2, and 20 mmol/L 2-(N-morpholino)ethanesulfonate (MES;
pH 5.5), were added to the well and incubated for 1 h at 37°C. Unbound LDL
was removed, the wells were washed with MES-buffered saline, and bound
LDL was determined by the Amplex Red Cholesterol Assay (Invitrogen). LDL
aggregation was studied by following aggregation by light scattering at 680 nm
induced by vortex mixing of LDL solutions (20,21).
Cell culture studies. Cellular receptor and nonreceptor binding of LDL were
studied in cultures of human BJ ﬁbroblasts, hepatocyte-like HepG2 cells, and
THP1 macrophages. HepG2 cells and BJ ﬁbroblasts (22) were grown in min-
imum essential medium (MEM) supplemented with 10% (v/v) FBS, penicillin
(100 units/mL), and streptomycin (100 mg/mL) at 37°C in 95% O2/5% CO2 and
100% humidity under aseptic conditions in 12-well plates. Cells were washed
with Ca
2+- and Mg
2+-free Hanks’ balanced salt solution and incubated with
1.0 mL of MEM containing 20% lipoprotein-deﬁcient serum (LPDS) for 24 h
before each experiment.
Surface binding of LDL was determined at 4°C. Cells (8 3 10
5) were in-
cubated with 5 to 160 mg/mL LDL with 1 mg/mL [
125I]LDL tracer in MEM
containing 10% LPDS for 3 h. After incubation, cells were washed thrice and
FIG. 1. MG-modiﬁed LDL has decreased particle size and increased susceptibility to aggregation and arterial proteoglycan binding. A: Reaction of
MG with arginine residues form hydroimidazolone MG-H1. B: Electron micrograph of MGmin-LDL (original magniﬁcation 325,000). C: Vortex
mixing-stimulated aggregation of LDL: time course—unmodiﬁed LDL (-□-□-) and MGmin-LDL (-■-■-). D: Comparison of aggregation after 20 s for
unmodiﬁed LDL (Control), MGmin-LDL, and oxidized LDL. Proteoglycan binding in cell-free system is shown for biglycan (E), aggrecan (F), and
perlecan (G). □, Unmodiﬁed LDL; ■,M G min-LDL; ○,M G min-LDL prepared in the presence of aminoguanidine (500 mmol/L); △, glucose-modiﬁed
LDL, AGEmin-LDL. Data are mean 6 SD (n =3 ) .
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4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid buffer, and 10 mg/mL
heparin. The medium was removed and counted for determination of heparin-
displaceable LDL. The cells were washed thrice again, dissolved in 0.5 mL of
100 mmol/L NaOH, and counted to determine non–heparin-displaceable LDL.
Where speciﬁc binding was determined, LDL binding in the presence of
a 10-fold excess of cold LDL was subtracted (23). Some experiments involved
preincubation for 2 h with heparinase III (0.2 units/mL) or sodium chlorate
(10 mmol/L) for 24 h to remove heparan sulfate and prevent glycosamino-
glycan sulfation, respectively. Speciﬁc binding was calculated by subtracting
the amount of a nonspeciﬁc binding, as determined in the presence of a 10-fold
excess of unlabeled LDL or MGmin-LDL. Competitive inhibition of LDL or
MGmin-LDL binding was investigated by incubation of [
125I]LDL or [
125I]MGmin-
LDL in the presence of 0 to 80 mg/mL of unlabeled MGmin-LDL or LDL prep-
arations, respectively.
Plasma clearance and aortal retention of LDL in vivo. Plasma clearance
and aortal binding of LDL and MGmin-LDL was studied in rats. [
125I]LDL or [
125I]
MGmin-LDL (;1 3 10
6 cpm) was injected in the tail vein of 28 male SD rats
(body wt ;250 g; Charles River, Margate, U.K.), with and without heparinase
III injection 24 h earlier (24). Blood samples (0.20 mL) were taken from the tail
vein at 1, 2, 4, 8, 12, 24, 48, and 72 h, and counted for radioactivity. After the
last blood sample, rats were killed, and the aorta was removed. This experi-
mentation was performed on U.K. Home Ofﬁce project license no PPL40/3260.
Analysis of atherosclerotic lesions in aorta of apo E–deﬁcient mice.
Aortal localization of MG-modiﬁed protein was studied in diabetic athero-
sclerosis by immunoblotting of aorta of streptozotocin-induced apoE–deﬁcient
(
2/2) mice being fed a high-fat diet (Supplementary Data).
Peptide mapping of MG modiﬁcation hotspot of apoB100 of LDL. The
hotspot of MG modiﬁcation in apoB100 was located by sequential limited
proteolysis with trypsin and Lys-C of delipidated LDL, MGmin-LDL, and two-
dimensional chromatography with mass spectrometry peptide mapping. LDL
(250 mg in 100 mmol/L ammonium bicarbonate [pH 8], 90 mL) was incubated
with dithiothreitol (10 mmol/L, 10 L) at room temperature for 1 h. Sodium
iodoacetamide (100 mmol/L in water, 10 mL) was added, and samples were
incubated at room temperature in the dark for 1 h. The LDL solution was
transferred to a glass vial containing butylated hydroxytoluene in methanol
(5 mL, 2 mg/mL) and 20% trichloroacetic acid (105 mL), mixed well, left on ice
for 10 min, and centrifuged at 10,000g for 15 min at 4°C. The supernatant was
removed. The pellet was washed with acetone (200 mL) and diethyl ether
(200 mL) and dried under argon.
The remaining apoB100 precipitate was suspended in 100 mL of 50 mmol/L
ammonium bicarbonate (pH 8) containing 0.1% (w/v) surfactant RapiGest
(Waters, Watford, U.K.). Trypsin (1 mg/mL, 6 mL) was added and incubated
under argon at 37°C in the dark for 2 h with shaking. The digested sample
(suspension of digested LDL) was mixed with 1% formic acid in 10% aceto-
nitrile (1:1, v/v), centrifuged at 10,000g for 5 min, and the peptide-containing
supernatant was retained.
The tryptic digest (45 mL, 106 mg) was fractionated by gel permeation
chromatography (Shodex 2 x KW-800 series, 300 3 8-mm columns in series
with a KW-G, 6 3 50-mm guard column; Showa Denko, Tokyo, Japan). The
mobile phase was 100 mmol/L Na2H2PO4, 140 mmol/L NaCl (pH 7.4), the ﬂow
rate was 1 mL/min, and fractions were collected and lyophilized. Peptides
were extracted from residual salts by methanol, and solvent was removed
under reduced pressure. Half of the recovered peptides were digested ex-
haustively, and MG-H1 and arginine content were quantiﬁed by stable isotopic
dilution analysis liquid chromatography-tandem mass spectrometry (LC-MS/
MS) (16).
The fraction with the highest MG-H1/arg content was further digested with
endopeptidase Lys-C (peptide: protease ratio of 50:1) under argon at 37°C
(pH 7.4) in the dark for 2 h. The Lys-C digest was lyophilized, reconstituted
in 0.1% triﬂuoroacetic acid, and desalted (C18 ZipTip pipette tips, Millipore,
Billerica, MA). Digests were analyzed by nanoﬂow liquid chromatography-ion
trap mass spectrometry with alternating collision-induced dissociation (CID)
and electron transfer dissociation (ETD) peptide fragmentation: EASY-nLC
interface, ﬂow rate of 300 nL/min, with ﬂuoranthene electron/proton donor-
AmaZon mass spectrometer (Bruker Daltonics, Bremen, Germany). CID frag-
mentation was controlled by SmartFrag (Bruker Daltonics). ETD fragmentation
was performed with 500,000 counts of ﬂuoranthene present in the trap for 100
ms and Smart Decomposition set to auto. Spectra were processed using Data-
Analysis (Bruker), and the resulting peak lists were subjected to database
searching using Mascot (Matrix Sciences, London, U.K.). Good peptide frag-
mentation was observed, and peptide Mascot scores were .15. Peptides were
present throughout the 500-kDa sequence of the protein.
Molecular modeling. R18 of the predicted structure of the N-terminal 300
amino acid residue domain of human apoB100, deduced from sequence sim-
ilarity with vertebrate lipovitellin (25), was modiﬁed to an MG-H1 residue.
Energy minimization and molecular graphics representation were performed
using DS Viewer Pro 5.0 (Accelrys, San Diego, CA).
Statistical analysis. Data are mean 6 SD for parametric data and median
(upper–lower quartile) for nonparametric data. Signiﬁcance of difference be-
tween mean changes was assessed by Student t test and between median
changes by Mann-Whitney U test.
RESULTS
Minimal modiﬁcation of LDL by MG decreases particle
size and increases tendency toward aggregation and
binding afﬁnity for arterial PGs. MGmin-LDL had 1.6
molar equivalents of MG modiﬁcation, 98% of which was
MG-H1 (16). Modiﬁcation of LDL by MG produced a signif-
icant decrease in LDL particle size, similar to that of sdLDL
(26) (Fig. 1B, Table 1). Glycation of LDL by glucose and
glycation of LDL by MG in the presence of aminoguanidine,
a MG scavenger (27), were without similar effect. MG
modiﬁcation did not change the cholesterol and tri-
glyceride content of LDL.
We next investigated whether MGmin-LDL had increased
tendency to aggregate and bind PGs. Aggregation of LDL
is stimulated experimentally by vortex mixing solutions
of LDL. When vortexed for 0 to 40 s, MGmin-LDL showed
a greater rate and extent of aggregation than unmodiﬁed
LDL (Fig. 1C). Glycation by glucose and glycation by MG
in the presence of aminoguanidine produced LDL deriva-
tives that were without similar effect. Oxidized LDL was
more susceptible to aggregation than MGmin-LDL in this
evaluation (Fig. 1D). Arginine-directed glycation by MG,
however, is a novel nonoxidative modiﬁcation that stim-
ulates LDL aggregation.
We investigated binding of LDL derivatives to vascular
PGs, including the class I small leucine-rich biglycan, the
large extracellular PG aggrecan, and the basement mem-
brane PG perlecan; these PGs are all found in regions of
atherosclerotic plaque development (28,29). In the cell-
free system, MGmin-LDL had a higher binding afﬁnity for
biglycan than unmodiﬁed LDL, glucose-modiﬁed LDL, and
LDL modiﬁed by MG in the presence of aminoguanidine
(Fig. 1E). MGmin-LDL also had increased binding to aggre-
can and perlecan than the unmodiﬁed control LDL (Fig. 1F
and G).
TABLE 1
Effect of MG modiﬁcation on the physicochemical characteristics of LDL
Variable
Control LDL MGmin-LDL
P n Mean 6 SD n Mean 6 SD
LDL size (nm) 70 29.1 6 1.8 70 26.0 6 1.7 ,0.001
+Aminoguanidine 20 28.4 6 1.5 20 27.9 6 1.3 0.33
Cholesterol (mmol/mg protein) 6 2.34 6 0.07 6 2.29 6 0.18 0.62
Triglycerides (mmol/mg protein) 4 0.127 6 0.018 4 0.133 6 0.027 0.21
TBARS (nmol/mg protein) 4 0.67 6 0.14 5 0.68 6 0.12 0.88
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LDL receptor and increases binding to cell surface
heparan sulfate–containing PGs. Binding of LDL to
the LDL receptor mediates particle entry into cells (30).
We assessed whether MG modiﬁcation of LDL impaired
this process by studying binding of MGmin-LDL to human
hepatocyte-like HepG2 cells and BJ ﬁbroblasts in vitro. Cell
binding of MGmin-LDL to HepG2 and BJ cells was not sig-
niﬁcantly different from that of unmodiﬁed LDL (Fig. 2A
and B, respectively). Binding of MGmin-LDL was competitive
with unmodiﬁed LDL, and both had similar afﬁnity con-
stants for speciﬁc binding (Supplementary Data). This
indicates that MG modiﬁcation of LDL does not impair
uptake of LDL at normal physiologic sites. In the same
cells, however, heparin-displaceable binding of MGmin-
LDL was increased compared with that of unmodiﬁed
LDL (Fig. 2C and D). This was blocked when heparan
sulfate was removed from the cell surface by prior in-
cubation with heparinase III (Fig. 2E and F)a n dw h e n
glycosaminoglycan sulfation was suppressed by prein-
cubation of cells with chlorate (Fig. 2G). This suggests
that MGmin-LDL has increased binding to heparan sulfate,
non-LDL receptor sites, on the surface of ﬁbroblasts and
hepatocytes.
MGmin-LDL and LDL had similar binding to human
monocyte-derived macrophages, which was not inhibitable
by scavenger receptor ligands, suggesting that MG modi-
ﬁcation does not mediate the recognition of LDL by scav-
enger receptors (Supplementary Data).
Minimal modiﬁcation of LDL by MG increases aortal
retention in vivo. We assessed if MGmin-LDL had in-
creased binding to arterial PGs in vivo. Radiotracer [
125I]
MGmin-LDL or unmodiﬁed [
125I]LDL was injected into rats
and plasma clearance of the lipoproteins determined.
Plasma clearance rates were similar for MGmin-LDL and
unmodiﬁed LDL (Fig. 2H). On termination of the plasma
clearance study, we assessed levels of radiotracer LDL de-
rivative in the aorta. MGmin-LDL had signiﬁcantly increased
FIG. 2. Preserved LDL receptor binding, increased cellular proteoglycan binding, and aortal retention of MG-modiﬁed LDL. Cell binding of LDL and
MGmin-LDL. Curves for non-heparin–displaceable binding are shown for HepG2 cells (A) and BJ cells (B). Curves are shown for heparin–
displaceable binding for HepG2 cells (C) and BJ ﬁbroblasts (D). The effect of heparinase III (Hep III) on heparin displaceable binding is shown for
HepG2 cells (E) and BJ ﬁbroblasts (F). G: Effect of chlorate inhibition is shown for PG sulfation on heparin-displaceable binding in HepG2 cells.
Effect is shown for MG modiﬁcation on plasma clearance (H) and aortal/plasma partitioning (I) in vivo. The latter is given as the ratio of
radiolabeled LDL: cpm per g wet weight aorta/cpm per mL blood at sacriﬁce. -□-□-o r□ bar, Unmodiﬁed LDL; -■-■-o r■ bar, MGmin-LDL. Data
are mean 6 SD (n =3 –6). Plasma LDL radioactivity (cpm) was ﬁt to a single exponential decay curve. *P < 0.05 and **P < 0.01 (t test).
ATHEROGENICITY OF LDL MODIFIED BY METHYLGLYOXAL
1976 DIABETES, VOL. 60, JULY 2011 diabetes.diabetesjournals.orgpartitioning from blood to the aorta (Fig. 2I). This was
abolished by prior treatment with heparinase III, suggesting
that MG modiﬁcation of LDL increases retention of LDL in
the arterial wall at heparan sulfate–containing PGs.
A well-studied model of diabetic atherogenesis is the
high-fat “Western diet” streptozotocin-induced diabetic
apo E
2/2 mouse (30). Serum glucose concentration was
;40 mmol/L, indicative of frank hyperglycemia. Serum
LDL was increased 7.5-fold and serum MG concentration
63% (Supplementary Data). We previously found the rate
of modiﬁcation of LDL by MG, rMG-LDL, was directly pro-
portional to concentrations of MG and LDL (16) and hence
rMG-LDL =k MG,LDL[MG][LDL] where [MG] and [LDL] are
concentrations of MG and LDL, respectively, and kMG,LDL
is the rate constant for the glycation of LDL by MG. The
increased concentrations of LDL and MG combine in
streptozotocin-induced diabetic apoE
2/2 mice, therefore,
to give a predicted ;12-fold increase of the in situ rate of
MG modiﬁcation of LDL, relative to nondiabetic controls.
We examined the location of MG-H1 in sections of aorta of
diabetic and control apoE
2/2 mice by immunohistochem-
istry. Typical aortal sections showed increased staining for
MG-H1 in diabetic mice compared with healthy controls
(Fig. 3A and B).
Site of modiﬁcation of apoB100 of LDL by MG and
predicted impact on structure. The location of MG-H1
residues in apoB100 of MGmin-LDL was sought. The pres-
ence of MG-H1 residues in apoB100 was conﬁrmed by
LC-MS/MS of exhaustive enzymatic digests (16) (Fig. 3C
and D). Glycation of LDL by MG in the presence of heparin
did not decrease MG-H1 formation, consistent with the
primary site of glycation being located outside of the PG
binding site in apoB100 although capable of allosteric in-
teraction with it. We delipidated MGmin-LDL and digested
the resultant apoB100 with trypsin and fractionated tryptic
peptides by gel permeation chromatography. Trypsiniza-
tion of apoB100 is relatively ineffective (31), albeit im-
proved in the presence of surfactant RapiGest, and large
peptides remained (Fig. 3E). In replicate subsequent Lys-C
digests (n = 4) of MG-H1–rich fractions, MG modiﬁcation
was detected in peptide DATRMG-H1FK (residues 15–20) of
apoB100 extracted from MGmin-LDL and not from digests
of unmodiﬁed LDL (Fig. 3F). For identiﬁcation, this pep-
tide fragmented with CID and all b- and z-ions were
detected (Fig. 3G). Further supporting evidence was de-
tection of a related MG-H1 peptide DATRMG-H1FKHLRK
(M+2H)
2+, m/z = 663.54 from MGmin-LDL and unmodiﬁed
dipeptide (M+2H)
2+, m/z = 636.43, from LDL. This identi-
ﬁed R18 a target of MG modiﬁcation in apoB100 as site B-1a
(residues 15–25).
To assess the structural consequences of MG modiﬁca-
tion of LDL, a molecular graphics prediction of the struc-
ture of the MG-modiﬁed apoB100 was made. A molecular
model was derived from structural similarity of this region
of apoB100 to lipovitellin (25) located R18 at the terminal
focus of a lattice of seven parallel b-strands. R18 has an
intraresidue hydrogen bond (carbonyl O–dNH, bond length
2.29 Å) and a weak ionic interaction with the phenolic OH
group of Y27 (bond length 2.94 Å). The PG-binding domain,
site B-Ib (84–94), lies at the edge of the seven parallel
b-strand lattice held to it by hydrogen bonding of residues
L72–K88 and E74–L86 bond lengths 1.78 and 1.87 Å, re-
spectively (Fig. 3H). With MG modiﬁcation, the seven
b-strands are all partially distorted and interactions with
R18MG-H1 are broken. The PG-binding site B-Ib is raised ;2Å
on the surface as hydrogen bonding interactions with
L72 and E74 are lost (Fig. 3G and H). This provides in-
creased exposure of site B-Ib and likely explains the in-
creased binding afﬁnity of MGmin-LDL to PGs.
DISCUSSION
This study identiﬁed a novel endogenous modiﬁcation of
LDL, converting it to the proatherogenic form, increasing
binding to arterial PGs, and thereby producing increased
retention of LDL in the arterial wall.
The decrease in particle size of MGmin-LDL with re-
tention of mass of the major components is interpreted as
an increase in density, and hence, MGmin-LDL is a new type
of sdLDL. Measurements of LDL subfraction diameters
by electron microscopy established that the mean parti-
cle diameter decreases with increasing density (32). Re-
cent studies suggest that the LDL particle has a ﬂattened
discoidal shape, with the wide circumference surface a
high-density region containing apoB100. Part of apoB100
protrudes into the solvent, producing a lower-density re-
gion (33). We speculate that MG modiﬁcation has the effect
of decreasing the protrusion and increasing particle density.
A loss of cholesterol esters and a decreased cholesterol/
apoB100 ratio is often found in sdLDL in vivo. This is partly
linked to the triglyceride/cholesterol ester exchange by the
cholesterol ester transfer protein (5). This is not available in
the conversion of LDL to sdMGmin-LDL in vitro, and so the
cholesterol/apoB100 ratio remains unchanged.
Modiﬁcation of LDL by MG was directed to arginine
residues of the protein component—mainly apoB100—
forming hydroimidazolone MG-H1 residues. This modiﬁ-
cation is nonoxidative and, hence, does not form oxidized
LDL, as judged by the lack of increase in TBARS content;
nor was there an increase in methionine sulfoxide, dityro-
sine, and 3-nitrotyrosine, which are markers of protein
oxidation (16). MG may modify basic phospholipids, phos-
phatidylethanolamine, and phosphatidylserine (34). There
appeared to be little modiﬁcation of nonprotein sites,
however, because the estimation of total MG adducts in
MGmin-LDL by preparation with radiolabeled [
14C]MG was
similar to the total increase in MG-derived AGEs. By facil-
itating trapping of LDL by arterial PG, however, MG modi-
ﬁcation may promote LDL oxidation indirectly (35). LDL
was decreased in size by 11% on modiﬁcation by MG, sug-
gesting that MG modiﬁcation of LDL causes particle re-
modelling to an atherogenic form. The sdLDL particles
gain entry and are retained in the arterial wall, especially
at sites of atherosclerotic plaque lesion development (36).
The initial stages of atherosclerosis in the arterial wall
involve the accumulation of aggregates of small lipid
droplets and vesicles of up to 400 nm in diameter in the
extracellular matrix and the binding of these to PGs (20,21).
Characteristic of atherogenic sdLDL, MG-modiﬁed LDL
had an increased tendency to form aggregates and in-
creased binding afﬁnity for arterial PGs and cell surface
heparan sulfate (10). PG binding has been implicated in
subendothelial retention of LDL in animal models of ath-
erogenicity (37).
Chemical modiﬁcation of LDL by arginine-speciﬁcm o d i -
fying agents has been investigated previously. A non-
physiologic arginine-modifying agent, 1,2-cyclohexandione,
was used, and LDL with extremely high supraphysiologic
extents of modiﬁcation was prepared: ;66 mol adducts
per mol of LDL (44% of total arginine residues). This mod-
iﬁed LDL at sites other than the hotspot site discovered in
this study and thereby produced a markedly abnormal LDL
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This masked the effects we found. LDL in vivo has one
MG-H1 modiﬁcation on 2–12% of total LDL (16), and hence,
the minimal modiﬁcation of MGmin-LDL is appropriate to
model MG modiﬁcation in vivo.
Hotspot modiﬁcation by MG was located at R18 in
apoB100 of LDL. This is the ﬁrst example of post-translation
modiﬁcation at site B-Ia enhancing LDL binding to PG.
Molecular graphics analysis suggested that R18 is a critical
stabilizing residue in this domain, and loss of charge after
FIG. 3. Aortal accumulation of MG-H1 in diabetic atherosclerosis and proteomic and structural basis of functional change in MG modiﬁed LDL.
A and B: Confocal photomicrographs show sectioned aorta in healthy apoE
2/2 mice immunostained for endogenous MG-H1: healthy control mouse
(A) and diabetic mouse being fed a high-fat diet (B). Immunostaining was visualized with Alexa488 secondary antibody conjugate (green) and
nuclei are stained with DAPI (blue). Original magniﬁcation 363; scale bar = 20 mm. Images shown are representative of study group mice (n =7 ) .
Proteomic analysis of MG-modiﬁed LDL. Detection of MG-H1 in exhaustive enzymatic digests of MGmin-LDL shows MG-H1 (C) and internal
standard [
15N2]MG-H1 (both showing two partially resolved epimers) (D) (15,16). Peptide mapping of apoB100 of MGmin-LDL shows ﬁrst di-
mension chromatography with exhaustive proteolysis locating peptide fractions enriched in MG-H1 (E); detection of MG-H1 in peptide DATRFK at
R18, m/z = 791.40: molecular ion (F) and related CID fragmentation spectrum (G). Structural basis of functional change in MG-modiﬁed LDL.
Molecular models of human apoB100 residues 1–300 are shown for unmodiﬁed apoB100 (H), and MG-modiﬁed apoB100 (I). Red cylinders, a-helix;
cyan arrows, b-sheets (arrows point to C-terminus); PG binding domain (residues 84–94), green space, ﬁll; and R18 or MG-H1-18, space, ﬁll atom
color-coded. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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ture, with increased protrusion of the site binding PG on
the protein surface. Increased modiﬁcation of LDL by MG
in diabetic apoE
2/2 mice is also expected because murine
apoB48 residues 1–2152 of apoB100, the major protein of
LDL in apoE
2/2 mice (39), has high sequence homology
with the same domain of human apoB100 (40), and in situ
concentrations of LDL and MG were increased. Although
MG modiﬁcation of LDL is not an oxidative modiﬁcation,
diabetic apoE
2/2 mice suffer oxidative stress, as indicated
by a threefold increase of urinary isoprostanes (41). In-
creased retention of LDL in the arterial wall by MG mod-
iﬁcation may synergize with increased oxidative stress to
produce increased oxidized LDL in the arterial wall and
escalation of atherosclerosis.
MG modiﬁcation of LDL likely contributes to the in-
creased atherogenicity of LDL in diabetes (16). Agents that
scavenge MG, such as metformin, aminoguanidine, and
thiazolium compounds, prevented the development of ath-
erosclerosis in diabetic apoE
2/2 mice (27,42,43). Irbesartan,
an angiotensin II receptor blocker, decreased the forma-
tion of MG-derived MG-H1 in clinical diabetes (44) and
decreased the development of atherosclerotic plaques in
diabetic apoE
2/2 mice (45). Treatment with high-dose
thiamine supplements might be expected to prevent di-
abetic atherosclerosis because this treatment corrected
increased MG and dyslipidemia in experimental diabetes
(46,47), but this remains to be evaluated. MG is increased
in the plasma of patients with diabetes (12) but less in
patients treated with metformin (17), with concomitant
l o w e r e dr i s ko fC V D( 4 8 ) .
Metformin has an antiatherogenic effect that has hitherto
been unexplained, but results from this study show it is likely
due to a decrease of MG-modiﬁed LDL (16). Metformin
treatment of patients with type 2 diabetes also decreased
sdLDL (49). The nonoxidative nature of the MG modiﬁcation
may partly explain why antioxidant intervention to prevent
CVD has been less effective than expected (50). Quantitation
of MG-modiﬁed LDL may improve epidemiologic CVD risk
models, and therapeutics to decrease plasma MG may im-
prove current treatment to decrease CVD in diabetes, renal
failure, and in healthy people.
ACKNOWLEDGMENTS
This project was supported by the British Heart Founda-
tion with a personal fellowship to N.R. and a project grant,
and also by Heart and Stroke Foundation of Canada grant
T6110 to R.M.
No potential conﬂicts of interest relevant to this article
were reported.
N.R. designed the study (except for the apoE
2/2 mice
study), contributed to data interpretation, participated in
experimentation, wrote and reviewed the manuscript, and
approved the ﬁnal version. L.G. and M.X. participated in
experimentation, contributed to data interpretation, re-
viewed the manuscript, and approved the ﬁnal version.
F.S. processed and analyzed aortal samples in the apoE
2/2
study, contributed to data interpretation, reviewed the
manuscript, and approved the ﬁnal version. M.G. performed
the apoE
2/2 mice study, contributed to data interpretation,
reviewed the manuscript, and approved the ﬁnal version.
R.M. designed the apoE
2/2 study, contributed to data
interpretation, reviewed the manuscript, and approved
the ﬁnal version. P.J.T. designed the study (except for
the apoE
2/2 mice study), assisted the other authors with
experiments, contributed to data interpretation, wrote
and reviewed the manuscript, and approved the ﬁnal
version.
Parts of this study were submitted for presentation at the
71st Scientiﬁc Sessions of the American Diabetes Associa-
tion, San Diego, California, 24–28 June 2011.
The authors thank Dr. Julia Smith (Bruker, Coventry,
U.K.); Dr. Naomi Yamada-Fowler, Dr. Muhammad Maqsud
Anwar, and Tim Orton (Warwick Medical School); and Ian
Portman (Imaging Services, Warwick Life Sciences) for
technical assistance. The authors thank Professor Jere
Segrest (University of Alabama, Birmingham, AL) and Dr.
Paul E. Richardson (Coastal Carolina University, Conway,
SC) for provision of the Protein Data Bank ﬁle of the
predicted structure of N-terminal 300 amino acid sequence
of human apoB100.
REFERENCES
1. Rizzo M, Berneis K, Corrado E, Novo S. The signiﬁcance of low-density-
lipoproteins size in vascular diseases. Int Angiol 2006;25:4–9
2. Tan CE, Chew LS, Chio LF, et al. Cardiovascular risk factors and LDL sub-
fraction proﬁle in type 2 diabetes mellitus subjects with good glycaemic
control. Diabetes Res Clin Pract 2001;51:107–114
3. Skoglund-Andersson C, Tang R, Bond MG, de Faire U, Hamsten A, Karpe
F. LDL particle size distribution is associated with carotid intima-media
thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol 1999;
19:2422–2430
4. Rizzo M, Pernice V, Frasheri A, et al. Small, dense low-density lipo-
proteins (LDL) are predictors of cardio- and cerebro-vascular events in
subjects with the metabolic syndrome. Clin Endocrinol (Oxf) 2009;70:
870–875
5. Berneis KK, Krauss RM. Metabolic origins and clinical signiﬁcance of LDL
heterogeneity. J Lipid Res 2002;43:1363–1379
6. Rizzo M, Berneis K, Koulouris S, et al. Should we measure routinely oxi-
dised and atherogenic dense low-density lipoproteins in subjects with type
2 diabetes? Int J Clin Pract 2010;64:1632–1642
7. de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Identiﬁcation of
multiple dense LDL subfractions with enhanced susceptibility to in vitro
oxidation among hypertriglyceridemic subjects. Normalization after cloﬁ-
brate treatment. Arterioscler Thromb 1993;13:712–719
8. Scheffer PG, Bos G, Volwater HG, Dekker JM, Heine RJ, Teerlink T.
Associations of LDL size with in vitro oxidizability and plasma levels of
in vivo oxidized LDL in type 2 diabetic patients. Diabet Med 2003;20:563–
567
9. Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ. Interaction of
very-low-density, intermediate-density, and low-density lipoproteins with
human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol 1997;17:
2507–2514
10. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small
dense low density lipoprotein has increased afﬁnity for LDL receptor-
independent cell surface binding sites: a potential mechanism for increased
atherogenicity. J Lipid Res 1998;39:1263–1273
11. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects
Med 1993;14:287–371
12. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. Glyoxalase system in
clinical diabetes mellitus and correlation with diabetic complications. Clin
Sci (Lond) 1994;87:21–29
13. Thornalley PJ. Modiﬁcation of the glyoxalase system in human red blood
cells by glucose in vitro. Biochem J 1988;254:751–755
14. Thornalley PJ. Dietary AGEs and ALEs and risk to human health by their
interaction with the receptor for advanced glycation endproducts (RAGE)
—an introduction. Mol Nutr Food Res 2007;51:1107–1110
15. Thornalley PJ. Dicarbonyl intermediates in the Maillard reaction. Ann N Y
Acad Sci 2005;1043:111–117
16. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ.
Increased glycation and oxidative damage to apolipoprotein B100 of LDL
cholesterol in patients with type 2 diabetes and effect of metformin. Di-
abetes 2010;59:1038–1045
17. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metfor-
min reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes
1999;48:198–202
18. Couchman JR, Kapoor R, Sthanam M, Wu RR. Perlecan and basement
membrane-chondroitin sulfate proteoglycan (bamacan) are two basement
N. RABBANI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JULY 2011 1979membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth-
Holm-Swarm tumor matrix. J Biol Chem 1996;271:9595–9602
19. Sneck M, Kovanen PT, Oörni K. Decrease in pH strongly enhances binding
of native, proteolyzed, lipolyzed, and oxidized low density lipoprotein
particles to human aortic proteoglycans. J Biol Chem 2005;280:37449–
37454
20. Oörni K, Pentikäinen MO, Ala-Korpela M, Kovanen PT. Aggregation, fu-
sion, and vesicle formation of modiﬁed low density lipoprotein particles:
molecular mechanisms and effects on matrix interactions. J Lipid Res
2000;41:1703–1714
21. Pentikäinen MO, Lehtonen EM, Kovanen PT. Aggregation and fusion of
modiﬁed low density lipoprotein. J Lipid Res 1996;37:2638–2649
22. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-
density lipoprotein in cultured cells. Methods Enzymol 1983;98:241–260
23. Cho BHS, Dokko RC, Chung BH. Oleic, linoleic and linolenic acids en-
hance receptor-mediated uptake of low density lipoproteins in Hep-G2
cells. J Nutr Biochem 2002;13:330–336
24. Silver PJ, Moreau JP, Denholm E, et al. Heparinase III limits rat arterial
smooth muscle cell proliferation in vitro and in vivo. Eur J Pharmacol
1998;351:79–83
25. Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, Borén J.
Identiﬁcation of the proteoglycan binding site in apolipoprotein B48. J Biol
Chem 2002;277:32228–32233
26. Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology:
low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin
Endocrinol Metab 2003;88:4525–4532
27. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the for-
mation of advanced glycation endproducts. Arch Biochem Biophys 2003;
419:31–40
28. Evanko SP, Raines EW, Ross R, Gold LI, Wight TN. Proteoglycan distri-
bution in lesions of atherosclerosis depends on lesion severity, structural
characteristics, and the proximity of platelet-derived growth factor and
transforming growth factor-beta. Am J Pathol 1998;152:533–546
29. Talusan P, Bedri S, Yang S, et al. Analysis of intimal proteoglycans in
atherosclerosis-prone and atherosclerosis-resistant human arteries by
mass spectrometry. Mol Cell Proteomics 2005;4:1350–1357
30. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol
2009;29:431–438
31. Yang CY, Kim TW, Weng SA, Lee BR, Yang ML, Gotto AM Jr. Isolation and
characterization of sulfhydryl and disulﬁde peptides of human apolipo-
protein B-100. Proc Natl Acad Sci USA 1990;87:5523–5527
32. Shen MMS, Krauss RM, Lindgren FT, Forte TM. Heterogeneity of serum
low density lipoproteins in normal human subjects. J Lipid Res 1981;22:
236–244
33. Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ. Apolipoprotein B-100
conformation and particle surface charge in human LDL subspecies: im-
plication for LDL receptor interaction. Biochemistry 1998;37:12867–12874
34. Shoji N, Nakagawa K, Asai A, et al. LC-MS/MS analysis of carboxymeth-
ylated and carboxyethylated phosphatidylethanolamines in human eryth-
rocytes and blood plasma. J Lipid Res 2010;51:2445–2453
35. Hurt-Camejo E, Camejo G, Rosengren B, et al. Effect of arterial proteo-
glycans and glycosaminoglycans on low density lipoprotein oxidation and
its uptake by human macrophages and arterial smooth muscle cells. Ar-
terioscler Thromb 1992;12:569–583
36. Björnheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipo-
protein fractions and subfractions in the arterial wall, determined in an in
vitro perfusion system. Atherosclerosis 1996;123:43–56
37. Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention
of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750–754
38. Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E.
Inhibition of lipoprotein binding to cell surface receptors of ﬁbroblasts
following selective modiﬁcation of arginyl residues in arginine-rich and B
apoproteins. J Biol Chem 1977;252:7279–7287
39. Webb NR, de Beer MC, de Beer FC, van der Westhuyzen DR. ApoB-containing
lipoproteins in apoE-deﬁcient mice are not metabolized by the class B
scavenger receptor BI. J Lipid Res 2004;45:272–280
40. Segrest JP, Jones MK, Mishra VK, et al. Apolipoprotein B-100: conservation
of lipid-associating amphipathic secondary structural motifs in nine spe-
cies of vertebrates. J Lipid Res 1998;39:85–102
41. Yi X, Maeda N. alpha-Lipoic acid prevents the increase in atherosclerosis
induced by diabetes in apolipoprotein E-deﬁcient mice fed high-fat/low-
cholesterol diet. Diabetes 2006;55:2238–2244
42. Zhang M, Song P, Guzman MR, Asfa S, Zou MH. Metformin attenuates
atherosclerosis in streptozotocin-induced diabetic ApoE-deﬁcient mice
through AMP-activated protein kinase. Diabetes 2009;58:A190
43. Forbes JM, Yee LTL, Thallas V, et al. Advanced glycation end product in-
terventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:
1813–1823
44. Rabbani N, Adaikalakoteswari A, Rossing K, et al. Effect of Irbesartan
treatment on plasma and urinary markers of protein damage in patients
with type 2 diabetes and microalbuminuria. Amino Acids. 8 March 2011
[Epub ahead of print]
45. Candido R, Allen TJ, Lassila M, et al. Irbesartan but not amlodipine sup-
presses diabetes-associated atherosclerosis. Circulation 2004;109:1536–
1542
46. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Pre-
vention of incipient diabetic nephropathy by high-dose thiamine and
benfotiamine. Diabetes 2003;52:2110–2120
47. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ. High-
dose thiamine therapy counters dyslipidaemia in streptozotocin-induced
diabetic rats. Diabetologia 2004;47:2235–2246
48. Bailey CJ. Metformin: effects on micro and macrovascular complications
in type 2 diabetes. Cardiovasc Drugs Ther 2008;22:215–224
49. Ohira M, Miyashita Y, Ebisuno M, et al. Effect of metformin on serum
lipoprotein lipase mass levels and LDL particle size in type 2 diabetes
mellitus patients. Diabetes Res Clin Pract 2007;78:34–41
50. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL;
Nutrition Committee of the American Heart Association Council on Nu-
trition, Physical Activity, and Metabolism. Antioxidant vitamin supple-
ments and cardiovascular disease. Circulation 2004;110:637–641
ATHEROGENICITY OF LDL MODIFIED BY METHYLGLYOXAL
1980 DIABETES, VOL. 60, JULY 2011 diabetes.diabetesjournals.org